Amferia earns ISO 13485 certification for wound care platform
The certification complements its FDA De Novo clearance and ensures quality throughout the product lifecycle.
See the latest news and media coverage for Amferia. We track all announcements, press releases, and industry mentions in real time, all in one place.
Antimicrobial peptide technology developer
amferia.comLast updated
In short: Amferia achieved FDA De Novo approval for its antibacterial wound dressing and secured €3.5M in funding to accelerate global expansion.
The certification complements its FDA De Novo clearance and ensures quality throughout the product lifecycle.
The portfolio of 50 applications spans four technology families, positioning the company for growth in antimicrobial wound care.
Randy Schwartz and Nikolaj Sørensen bring expertise in wound care commercialization and life science strategy.
The approval creates a new category for its peptide-based antibacterial wound dressing. Amferia attends EWMA Congress to discuss U.S. market expansion.
The American drug agency FDA has approved an antibacterial wound dressing from the Chalmers spin-off Amferia. Thus, the company is free to enter the American...
Atefyekta is a co-founder of Amferia, a medical device company that has developed a breakthrough technology using anti-microbial peptides to combat the rapid rise of...
Amferia is developing a new antibacterial material that is to be used in healthcare for, among other things, wound care, and is to be effective against many different types of...
Law firm Lindahl has assisted Amferia AB in entering into an exclusive private label license and supply agreement within animal health with Orkla Wound Care. The agreement - which...
Track Amferia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Amferia and other trending companies.